Photo via WCNC Charlotte
Octapharma, a Switzerland-based specialty pharmaceutical manufacturer, has chosen York County, South Carolina, as the location for its first U.S. manufacturing operation. According to WCNC Charlotte, the facility represents a significant expansion into American markets for the company, which specializes in plasma-derived and recombinant medicines. The decision underscores growing interest from international life sciences firms in establishing production operations within the Southeast region.
The York County location positions the facility within the broader Charlotte-adjacent biotech corridor, an area that has increasingly attracted pharmaceutical and life sciences investments. While full operations are not projected to begin until the mid-2030s, the multi-year development timeline suggests substantial capital investment and long-term commitment to the region. This timeline also indicates extensive planning, regulatory approvals, and infrastructure development will precede commercial manufacturing.
For Charlotte-area stakeholders, Octapharma's investment reflects the Southeast's growing appeal as a life sciences hub, potentially spurring additional healthcare manufacturing opportunities nearby. The project may generate construction jobs, skilled manufacturing positions, and supply chain opportunities for regional businesses. As biotech and specialty pharmaceutical operations continue clustering in the Southeast, developments like this could reinforce the Carolinas' position as a competitive destination for global healthcare companies seeking U.S. production capabilities.
